ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Oragenics Inc

Oragenics Inc (OGEN)

1.015
-0.005
(-0.49%)
Closed July 21 4:00PM
1.02
0.005
(0.49%)
After Hours: 6:07PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.02
Bid
-
Ask
-
Volume
93,005
1.01 Day's Range 1.0899
0.97 52 Week Range 7.74
Market Cap
Previous Close
1.02
Open
1.07
Last Trade
977
@
1.02
Last Trade Time
Financial Volume
$ 98,596
VWAP
1.0601
Average Volume (3m)
143,443
Shares Outstanding
4,480,693
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Oragenics Inc

Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other ho... Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and having other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering. It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Tampa, Florida, USA
Founded
1970
Oragenics Inc is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker OGEN. The last closing price for Oragenics was $1.02. Over the last year, Oragenics shares have traded in a share price range of $ 0.97 to $ 7.74.

Oragenics currently has 4,480,693 shares outstanding. The market capitalization of Oragenics is $4.57 million.

OGEN Latest News

Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients

SARASOTA, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...

Oragenics, Inc. Announces Closing of Public Offering

SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...

Oragenics, Inc. Announces Pricing of Public Offering

SARASOTA, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...

Oragenics, Inc. Announces Proposed Public Offering

SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal pharmaceuticals for the...

Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance

SARASOTA, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.13-11.30434782611.151.18511478321.10359122CS
4-0.55-35.03184713381.571.570.971500271.08279626CS
12-0.05-4.672897196261.073.430.971434431.80432482CS
26-4.03-79.8019801985.055.26870.971151231.79684545CS
52-2.55-71.42857142863.577.740.97648762.0520017CS
156-33.21-97.020157756434.23690.97100885536.65645805CS
260-27.282-96.396014415928.302127.20.97303539049.79220617CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
AUGXAugmedix Inc
$ 2.27
(147.71%)
21.87M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.76M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.13k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.63M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
223.27k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.93M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
28.43M
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
206.41M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
202.14M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
184.21M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
119.98M

OGEN Discussion

View Posts
Monksdream Monksdream 20 hours ago
OGEN under $2
👍️0
Monksdream Monksdream 3 months ago
OGEN under $2
👍️0
Monksdream Monksdream 4 months ago
OGEN 10Q due 3/19
👍️0
willlbone willlbone 6 months ago
China Dump
👍️0
JDCruz JDCruz 9 months ago
News just hit! Oragenics Issues Update to Shareholders:
https://www.otcmarkets.com/stock/OGEN/news/story?e&id=2676834
👍️0
JDCruz JDCruz 9 months ago
OGEN steady rise looks like this biotech is ready to run!
👍️0
retired early retired early 1 year ago
Will this turd float to the surface? :)
👍️0
retired early retired early 1 year ago
Maybe not. :)
👍️0
Nathan123456 Nathan123456 2 years ago
Don't madder they will short it down to nothing
👍️0
retired early retired early 2 years ago
Surfs up. ::)
👍️0
BEIJING BILL BEIJING BILL 2 years ago
Chart setup perfectly here -> time is koming for the super spike

https://stockcharts.com/h-sc/ui?s=ogen
👍️0
retired early retired early 2 years ago
Hey whatever it takes to see it rise to the moon but wow hats off to your sacrifice. :)
👍️0
THEMASTERS_SON THEMASTERS_SON 2 years ago
,,,,,,,I’m out
👍️0
unpathedhaunt unpathedhaunt 2 years ago
3/22 Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

"“We are thrilled to have begun this pivotal study with Frontage, a premier drug development contract research organization, and are thankful to the acceleration Frontage has offered our important IND-enabling study. We believe the results from this rabbit toxicology study will support our development strategy for our intranasal COVID-19 vaccine candidate, NT-CoV2-1. The intranasal delivery route is particularly relevant as it may further reduce transmission of the virus and provide a needle-free delivery option. The findings from this preclinical toxicology study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration,” said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics."


https://ir.oragenics.com/press-releases/detail/142

👍️0
BEIJING BILL BEIJING BILL 2 years ago
KABOOM !! ve got movement!!
👍️0
retired early retired early 2 years ago
Looks like word is getting out. :)
👍️0
retired early retired early 3 years ago
I agree. The buy consensus is at 83%.3 days ago. I think info is near. :)
👍️0
Nathans123 Nathans123 3 years ago
HUGE insider buy
👍️0
TheFinalCD TheFinalCD 3 years ago
OGEN HOD
👍️0
shurtha2000 shurtha2000 3 years ago
lets get this back over $1
👍️0
alisher alisher 3 years ago
Oragenics (OGEN) Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant

Agreement extends current licensing and collaboration agreement to include rapid production of Omicron-specific intranasal vaccine candidates

TAMPA, Fla., December 20, 2021--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue an intranasal vaccine designed to protect against the SARS-CoV-2 Omicron variant. The NRC cell expression technologies provide Oragenics with a platform that can generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern. This platform should allow production of cell lines within six to eight weeks of spike gene sequence availability, compared with six to nine months for traditional production of such cell lines. The NRC technologies, developed with support from the NRC’s Pandemic Response Challenge program, will expedite the evaluation of an Omicron-specific Terra-CoV-2 candidate in preclinical and clinical studies.

"Oragenics is well-positioned to develop an Omicron-specific intranasal vaccine thanks to our successful, on-going collaboration with the NRC," said Frederick W. Telling, Ph.D., Oragenics’ Executive Chairman. "We had anticipated the need for rapid development of COVID-19 vaccine candidates against new variants and can leverage the NRC cell expression platform to address Omicron and future variants."

Oragenics recently demonstrated the protection of hamsters against SARS-CoV-2 with the intranasal Terra-CoV-2 candidate, which strongly supports the further development into an IND-enabling GLP toxicology study and a first-in-human Phase 1 clinical study.

https://finance.yahoo.com/news/oragenics-extends-collaboration-national-research-130000929.html
👍️0
alisher alisher 3 years ago
Oragenics Announces Positive COVID-19 Challenge Study Results

Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced the results from its study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study. The study provided preclinical data for formulations designed for both intranasal and intramuscular administration.

Both formulations generated robust immune responses and reduced the SARS-CoV-2 viral loads to undetectable levels in the nasal passages and lungs five days following a viral challenge. By contrast, hamsters in the control groups that had received saline or adjuvants alone had no detectable immune response and substantial viral loads. The vaccines delivered by intranasal and intramuscular routes generated immune responses as measured by multiple assays.

"The very positive results from this hamster challenge study fully support our further development of either the intranasal or intramuscular routes of administration, however we plan to focus on the intranasal delivery route for the Terra CoV-2 vaccine due to the relative lack of competition and anticipated advantages of intranasal vaccine delivery, such as reducing viral transmission, needle-free administration, and ease of distribution, as well as the potential for conferred mucosal immunity which is presently being studied. The findings from this second preclinical study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration, expected to be made in the second quarter of 2022, and should facilitate advancement of the program into human clinical studies," said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics.

https://finance.yahoo.com/news/oragenics-announces-positive-covid-19-130000711.html
👍️0
Renegade Rich Renegade Rich 3 years ago
News!
👍️0
Mountainman5 Mountainman5 3 years ago
ORAGENICS is really on a good way to achieve soon $ 10 or more!!!!!!!!!!!!!!!!!!!!!!!!!!
👍️0
retired early retired early 3 years ago
Opps good call. I own both and posted on the wrong board. :)
👍️0
oakrock oakrock 3 years ago
How does that help OGEN?
👍️0
retired early retired early 3 years ago
Qiagen has received emergency use authorization from the U.S. Food and Drug Administration for its QIAreach SARS CoV-2 Antigen Test, which is designed for environments that require a high volume of fast and accurate test results. :)
👍️0
oakrock oakrock 3 years ago
OGEN will be a player....opportunity knocks.
👍️0
GREGG THE GREEK GREGG THE GREEK 3 years ago
Been a nice atm.


OGEN
👍️0
Lowhndcpr Lowhndcpr 3 years ago
What will happen today? Morning dip into low 70s to add?
Every time this stock runs….she sells off Next couple days. We shall see
👍️0
MADDSTACKER MADDSTACKER 3 years ago
Here comes eod volume
👍️0
shurtha2000 shurtha2000 3 years ago
$100-$200M from Canadian govt funding ?
👍️0
MADDSTACKER MADDSTACKER 3 years ago
Should thin out soon
👍️0
retired early retired early 3 years ago
EPIC :)
👍️0
MADDSTACKER MADDSTACKER 3 years ago
Could be epic
👍️0
bigbut bigbut 3 years ago
Big day looming here after OGEN announcement of work with Canadian Government on fast track vaccine alternatives.
👍️0
Lowhndcpr Lowhndcpr 3 years ago
Nice day here. Need to get back to a buck soon
👍️0
420man 420man 3 years ago
O-0
👍️0
dancy dancy 3 years ago
OGEN cover time
👍️0
ClayTrader ClayTrader 3 years ago
* * $OGEN Video Chart 04-23-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
retired early retired early 3 years ago
It's all about the therapeutics, peutics, peutics. :)
👍️0
trendzone trendzone 3 years ago
It's time for the CEO to get his head out of his toxic azz.
👍️0
DMOST DMOST 3 years ago
Past time.................But I can wait.

GO OGEN

"PEACE"
👍️0
oxnous oxnous 3 years ago
Time to.move up
👍️0
Golden Cross Golden Cross 3 years ago
Sorry, spike....
👍️0
geocam geocam 3 years ago
$OGEN Meandering up from the morning low on low volume. Any upcoming catalysts expected?

https://www.stockscores.com/charts/charts/?ticker=OGEN



below average volume
https://ih.advfn.com/stock-market/AMEX/oragenics-OGEN/historical
👍️0
DMOST DMOST 3 years ago
Filled at the gap............

GO OGEN

"PEACE"
👍️0
trendzone trendzone 3 years ago
Breaking news OGEN upgraded with a $2.75 PT

After-Hours Stock Movers 03/24: (RH) (OGEN) (FUL) Higher; (RAD) (EVFM) (KBH) Lower (more...)

March 24, 2021 5:40 PM

?

After-Hours Stock Movers

Rite Aid Corporations (NYSE: RAD) 17.9% LOWER; fourth quarter 2021 financial results were significantly impacted by a soft cough, cold and flu season, ongoing impacts related to COVID-19 and challenging weather conditions. As a result, the Company is updating its guidance for the fiscal year ended February 27, 2021.

Do this one thing with your money by April 30th

Sponsored By Stansberry Research

The next few weeks could affect your wealth for the next decade. Millions of Americans will be taken by surprise. Here’s what’s coming.

Evofem Biosciences, Inc. (NASDAQ: EVFM) 11.2% LOWER; announced that it intends to offer and sell, subject to market and other conditions, $30 million of shares of its common stock in an underwritten public offering

RH (NYSE: RH) 9.4% HIGHER; reported Q4 EPS of $5.07, $0.31 better than the analyst estimate of $4.76. Revenue for the quarter came in at $812.4 million versus the consensus estimate of $797.27 million.

Oragenics (NYSE: OGEN) 8% HIGHER; Ascendiant Capital assumes coverage with a Buy rating and a price target of $2.75.

H.B. Fuller (NYSE: FUL) 6.2% HIGHER; reported Q1 EPS of $0.66, $0.18 better than the analyst estimate of $0.48. Revenue for the quarter came in at $726 million versus the consensus estimate of $680.98 million.

KB Home (NYSE: KBH) 5.8% LOWER; reported Q1 EPS of $1.02, $0.10 better than the analyst estimate of $0.92. Revenue for the quarter came in at $1.14 billion versus the consensus estimate of $1.21 billion.

D8 Holdings Corp (NYSE: DEH) 2.7% HIGHER; Vicarious Surgical, a developer of medical robot tech that's backed by Bill Gates, is in talks to go public through a merger with blank-check firm D8 Holdings Corp (NYSE: DEH), according to a report from Bloomberg, citing a person with knowledge of the matter.

Full House Resorts, Inc. (Nasdaq: FLL) 2.7% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Wall Street Connected: Oriental Culture Holdings

Wall Street Connected: Oriental Culture Holdings

 

Latest Videos

?

Wall Street Connected: Oriental Culture Holdings

?

Looking at 10-Year Yields

?

Higher Yields, Stronger Dollar?

?

Categories

Special Reports

?

?

👍️0
DMOST DMOST 3 years ago
The gap set around 85 will have to eventually closed and then the share price recover before another substantial move upward?

Waiting to see what event initialized that move.....Another share offering, warrants, sells?

WE WILL WAIT TOO SEE.........

'peace'

However, more positive news trumps all...
👍️0
ClayTrader ClayTrader 3 years ago
* * $OGEN Video Chart 03-09-2021 * *

Link to Video - click here to watch the technical chart video

👍️0

Your Recent History

Delayed Upgrade Clock